Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

0 Hinnangud
0
Osa
598 of 1001
Kestus
16 min
Keel
inglise
Vorming
Kategooria
Majandus ja ettevõtlus

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.

Further Listening:

Trillion Dollar Shot

Why WeightWatchers Wants in on Drugs Like Ozempic

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices


Loe ja kuula

Astu lugude lõputusse maailma

  • Suurim valik eestikeelseid audio- ja e-raamatuid
  • Proovi tasuta
  • Loe ja kuula nii palju, kui soovid
  • Lihtne igal ajal tühistada
Proovi tasuta
Device Banner Block-copy 894x1036
Cover for Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Muud podcastid, mis võivad sulle meeldida ...